These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37746916)

  • 1. Association of ctDNA detection and recurrence assessment in patients with neoadjuvant treatment.
    Zhou J; Mo H; Hu D; Zhao X; Zhou H; Pan J
    Cancer Med; 2023 Oct; 12(19):19794-19806. PubMed ID: 37746916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis.
    Nader-Marta G; Monteforte M; Agostinetto E; Cinquini M; Martins-Branco D; Langouo M; Llombart-Cusac A; Cortés J; Ignatiadis M; Torri V; Apolone G; Cappelletti V; Pruneri G; de Azambuja E; Di Cosimo S
    ESMO Open; 2024 Mar; 9(3):102390. PubMed ID: 38460249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
    Crupi E; de Padua TC; Marandino L; Raggi D; Dyrskjøt L; Spiess PE; Sonpavde GP; Kamat AM; Necchi A
    Eur Urol Oncol; 2024 Feb; 7(1):44-52. PubMed ID: 37330413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of ctDNA Detection in Patients With Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis.
    Chang L; Zhang X; He L; Ma Q; Fang T; Jiang C; Ma Z; Li Q; Wu C; Tao J
    Oncologist; 2023 Dec; 28(12):e1198-e1208. PubMed ID: 37294663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing circulating tumour DNA (ctDNA) as a prognostic biomarker in locally advanced rectal cancer: a systematic review and meta-analysis.
    O'Sullivan NJ; Temperley HC; Kyle ET; Sweeney KJ; O'Neill M; Gilham C; O'Sullivan J; O'Kane G; Mehigan B; O'Toole S; Larkin J; Gallagher D; McCormick P; Kelly ME
    Int J Colorectal Dis; 2024 May; 39(1):82. PubMed ID: 38809315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
    Papakonstantinou A; Gonzalez NS; Pimentel I; Suñol A; Zamora E; Ortiz C; Espinosa-Bravo M; Peg V; Vivancos A; Saura C; Villacampa G; Oliveira M
    Cancer Treat Rev; 2022 Mar; 104():102362. PubMed ID: 35219090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis.
    Gögenur M; Hadi NA; Qvortrup C; Andersen CL; Gögenur I
    Ann Surg Oncol; 2022 Dec; 29(13):8666-8674. PubMed ID: 35933546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy.
    Chan WY; Lee JH; Stewart A; Diefenbach RJ; Gonzalez M; Menzies AM; Blank C; Scolyer RA; Long GV; Rizos H
    J Exp Clin Cancer Res; 2024 Aug; 43(1):238. PubMed ID: 39169411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.
    Wang B; Pei J; Wang S; Cheng K; Yu J; Liu J
    Crit Rev Oncol Hematol; 2022 Sep; 177():103771. PubMed ID: 35905822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse.
    Cailleux F; Agostinetto E; Lambertini M; Rothé F; Wu HT; Balcioglu M; Kalashnikova E; Vincent D; Viglietti G; Gombos A; Papagiannis A; Veys I; Awada A; Sethi H; Aleshin A; Larsimont D; Sotiriou C; Venet D; Ignatiadis M
    JCO Precis Oncol; 2022 Sep; 6():e2200148. PubMed ID: 36170624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Circulating Tumor DNA Dynamics Predict Neoadjuvant Therapy Response and Recurrence in Colorectal Liver Metastases: A Prospective Study.
    Wang XY; Zhang R; Han JH; Chen SQ; Zhao FL; Chen H; Lin J; Fan J; Zhu WW; Lu L; Chen JH
    Ann Surg Oncol; 2023 Aug; 30(8):5252-5263. PubMed ID: 37202570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
    Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
    Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
    Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
    PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence-a systematic review and meta-analysis.
    Chen Y; Mo S; Wu M; Li Y; Chen X; Peng J
    Int J Colorectal Dis; 2022 May; 37(5):1021-1027. PubMed ID: 35384496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Magbanua MJM; Swigart LB; Wu HT; Hirst GL; Yau C; Wolf DM; Tin A; Salari R; Shchegrova S; Pawar H; Delson AL; DeMichele A; Liu MC; Chien AJ; Tripathy D; Asare S; Lin CJ; Billings P; Aleshin A; Sethi H; Louie M; Zimmermann B; Esserman LJ; van 't Veer LJ
    Ann Oncol; 2021 Feb; 32(2):229-239. PubMed ID: 33232761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ctDNA as a predictor of outcome after curative resection for locally advanced rectal cancer: systematic review and meta-analysis.
    Nassar A; Aly NE; Jin Z; Aly EH
    Colorectal Dis; 2024 Jul; 26(7):1346-1358. PubMed ID: 38802990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.